Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cefatrizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 3/20 | 0.59 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefatrizine SCHEMBL27940222 | 0.97 | MAPT (0.61) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL49503 | 0.97 | MAPT (0.61) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL11671021 | 0.97 | MAPT (0.61) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL3688526 | 0.97 | MAPT (0.61) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL28000091 | 0.97 | MAPT (0.61) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL11247780 | 0.97 | MAPT (0.61) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL9580226 | 0.96 | MAPT (0.60) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL407704 | 0.96 | MAPT (0.58) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL10520664 | 0.96 | MAPT (0.60) | MAPTHSD17B10KMT2AMEN1SLC22A6 | |
| Cefatrizine SCHEMBL8116913 | 0.96 | PTGS1 (0.59) | MAPTHSD17B10KMT2AMEN1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043626-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230124705-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023056405-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2020006724-A1 | COMPOUND FOR TARGETED DEGRADATION OF FAK PROTEIN AND USE THEREOF | 清华大学 | 2020-01-09 | — | — | WO | disclosed |
| WO-2019228341-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| EP-1581467-B1 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2583958-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2583958-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Institute of Technology (MIT) (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-1581467-A4 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1002123-A1 | ENZYMATIC KINETIC RESOLUTION OF AN INTERMEDIATE USEFUL FOR PREPARING SUBSTITUTED TRICYCLICS | SCHERING CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| US-6037166-A | MULTISTEP PROCESS USING HYDROLASE AND ACYLATING AGENT; OPTIONALLY CONVERTING UNDESIRED ISOMERS INTO RACEMATE BY HEATING AND RESUBJECTING TO PROCESS; FOR ANTIHISTAMINES AND INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0696282-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF ANTIFUNGAL AGENTS | SCHERING CORP (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1998058073-A1 | ENZYMATIC KINETIC RESOLUTION OF AN INTERMEDIATE USEFUL FOR PREPARING SUBSTITUTED TRICYCLICS | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| US-5207876-A | Ketone, ether or ester extraction agents | Berg, Lloyd (US) | 1993-05-04 | — | — | US | disclosed |
| US-4778863-A | USING SOLVENT MIXTURE CONTAINING APROTIC SOLVENT AND EXCESS OF EPIHALOHYDRIN | THE DOW CHEMICAL COMPANY (US) | 1988-10-18 | — | — | US | disclosed |
| US-4524011-A | METHYLCHLOROFORM ROSIN WITH NO FLASH POINT | THE DOW CHEMICAL COMPANY (US) | 1985-06-18 | — | — | US | disclosed |
| US-4351973-A | Stabilized methylchloroform | THE DOW CHEMICAL COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| US-4309301-A | CORROSION RESISTANCE | THE DOW CHEMICAL COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4182920-A | CATION EXCHANGE RESIN CATALYST | THE DOW CHEMICAL COMPANY (US) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124705-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CYP11B2, CYP4A11, CYP11B1 | MAPT 1558/4885HSD17B10 221/4885KMT2A 1886/4885 |
| US-12043626-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP11B2, CYP4A11, CYP11B1 | MAPT 1558/4885HSD17B10 221/4885KMT2A 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.